News | April 09, 2009

NMT Medical’s STARFlex PMA Approved as Ventricular Septal Defect Repair Implant

April 9, 2009 - NMT Medical Inc. has received Pre-Market Approval (PMA) from the FDA to being commercial sales of the STARFlex cardiac septal repair implant for patients with ventricular septal defects (VSD).

STARFlex is constructed from a low profile, MP35N framework to which a knitted Dacron fabric is securely attached. The implant can be placed in the heart to close the VSD using a catheter during a minimally invasive procedure in the cath lab, providing an alternative to open-heart surgery.

Using spring coils in the framework, the STARFlex implant can be collapsed into a catheter for insertion into the heart. Once inserted through the catheter, the STARFlex implant is opened, with one umbrella positioned on each side of the defect. The design of the frame reportedly allows the device to conform to variations in the anatomy of the septum, keeping a low profile without obstructing the flow of blood through the atria.

For information: www.nmtmedical.com.

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology | December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology | November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Videos | Heart Valve Technology | November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Overlay Init